This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Mark Chiu, Ph.D.
President and CSO at Tavotek Biotherapeutics

Profile

Mark is the Chief Scientific Officer at Tavotek Biotherapeutics. He has nearly 35 years of experience in new drug discovery for AbbVie/Abbott Laboratories and Janssen. Prior to joining Tavotek, Dr. Chiu was the Head of the Process Analytical Sciences at Biotherapeutics Development and Head of Antibody Engineering in the Biologics Research Department at Janssen, the pharmaceutical branch of Johnson & Johnson (JNJ). His leadership resulted in more than 15 New Molecular Entities with 6 projects transitioning from Phase 1 to Phase 3 trials. Dr. Chiu received his B.S. in Biophysics from University of California at Berkeley; Ph.D. degree from the University of Illinois at Urbana-Champaign, and then completed postdoctoral training at the Laboratory of Physical Chemistry at the Federal Institute of Technology at Zurich, Switzerland and the Department of Microbiology at the University of Basel Biocentre.

Agenda Sessions

  • Three is a Magic Number: TAVO412 - A Novel Trispecific cMet x EGFR x VEGF Antibody for Difficult-to-Treat Cancers

    8:45am